Real-world experience in treatment outcome and genomic insights for metastatic prostate neuroendocrine carcinoma.

ABSTRACT:

Background

Neuroendocrine prostate cancer (NEPC) (de novo or treatment-related [t-NEPC]) is a rare and deadly variant of prostate cancer. While de novo NEPC is rare, t-NEPC occurs more frequently in patients with castration-refractory prostate cancer. Owing to the rarity of NEPC, no standard treatment has been established, and the outcomes are generally unsatisfactory.

Methods

This study retrospectively reviewed NEPC cases at Taipei Veterans General Hospital between 2018 and 2023. Clinical outcomes, treatment modalities, and related genomic profiles were recorded. We also performed a literature review of case series reporting the outcomes of chemotherapeutic regimens for NEPC.

Results

From 2158 cases of prostate cancer cases diagnosed during the study period, only 7 h

SUBMITTER: Lai JI 

PROVIDER: S-EPMC12718932 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature